0000905148-24-000774.txt : 20240221
0000905148-24-000774.hdr.sgml : 20240221
20240221162030
ACCESSION NUMBER: 0000905148-24-000774
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240220
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BRUNK GERALD A
CENTRAL INDEX KEY: 0001380226
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41854
FILM NUMBER: 24659818
MAIL ADDRESS:
STREET 1: C/O MDS CAPITAL
STREET 2: 245 FIRST ST., STE 1800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: enGene Holdings Inc.
CENTRAL INDEX KEY: 0001980845
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: Z4
FISCAL YEAR END: 1031
BUSINESS ADDRESS:
STREET 1: 4868 RUE LEVY, SUITE 220
CITY: SAINT-LAURENT
STATE: A8
ZIP: H4R 2P1
BUSINESS PHONE: (514) 332-4888
MAIL ADDRESS:
STREET 1: 4868 RUE LEVY, SUITE 220
CITY: SAINT-LAURENT
STATE: A8
ZIP: H4R 2P1
4
1
form4.xml
X0508
4
2024-02-20
0001980845
enGene Holdings Inc.
ENGN
0001380226
BRUNK GERALD A
C/O 4868 RUE LEVY, SUITE 220
SAINT-LAURENT
A8
H4R 2P1
QUEBEC, CANADA
true
true
false
Common Shares
2024-02-20
4
A
0
644965
10
A
993651
I
See Notes
Common Shares
2024-02-20
4
A
0
155035
10
A
238851
I
See Notes
Common Shares
1341790
I
See Notes
Common Shares
44647
I
See Notes
Common Shares
1077386
I
See Notes
Common Shares
152974
I
See Notes
These securities are held by Lumira Ventures IV, L.P. ("Lumira IV").
These securities are held by Lumira Ventures IV (International), L.P. ("Lumira IV Int'l").
These securities are held by Lumira Ventures III, L.P. ("Lumira III").
These securities are held by Lumira Ventures III (International), L.P. ("Lumira III Int'l").
These securities are held by Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira").
These securities are held by Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities").
Mr. Brunk is an executive officer of certain entities controlling and/or managing the Lumira Entities. Mr. Brunk disclaims beneficial ownership of the Common Shares held by the Lumira Entities, except to the extent of his pecuniary interest therein, if any. Lumira III and Lumira III Int'l are controlled by their general partner, Lumira Ventures III GP, L.P., and managed by Lumira Capital Investment Management Inc. ("Lumira Mgmt"). Lumira Ventures III GP, L.P. is controlled by its general partners, Lumira III GP Inc. and Lumira III GP Holdings Co. Lumira IV and Lumira IV Int'l are controlled by their general partner, Lumira IV GP 2020 Inc., and managed by Lumira Mgmt. Merck-Lumira and Merck-Lumira B are controlled by their general partner, Lumira Capital GP, L.P., and managed by Lumira Mgmt. (Continued in following footnote).
(Continued from prior footnote). Lumira Capital GP, L.P. is controlled by its general partners, Lumira GP Inc. and Lumira GP Holdings Co. Mr. Brunk is an executive officer of each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co. and Lumira Mgmt. Each of Lumira III GP Inc., Lumira III GP Holdings Co., Lumira IV GP 2020 Inc., Lumira GP Inc., Lumira GP Holdings Co., Lumira Mgmt and Mr. Brunk may be deemed to beneficially own the securities held by the respective Lumira Entities, but each disclaims beneficial ownership except to the extent of their respective pecuniary interests therein, if any.
/s/ Gerald Brunk
2024-02-21